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DID THE ADDITION OF CHEMOTHERAPY TO CONVENTIONAL 
RADIOTHERAPY IMPROVE OUTCOMES IN TREATMENT OF 
OROPHARYNX CANCER IN ONTARIO, CANADA – A MARKER-
TREATMENT INTERACTION STUDY? 
Stephen Hall1, Fei-Fei Liu2, Brian O'Sullivan2, Patti Groome1, 
Willa Shi2 
1Queen's University, Kingston, ON 
2University of Toronto, Toronto, ON 
 
Purpose: In 2001 the management of head and neck cancer 
abruptly changed with the addition of concurrent chemotherapy 
to radiotherapy based on randomized trials and meta-analyses. 
The role of Human Papilloma Virus (HPV) and its prognostic 
impact were subsequently identified in 2004. However there is 
no evidence on the efficacy of concurrent chemoradiotherapy 
(CRT) specifically for HPV positive or negative patients over 
conventional radiotherapy (RT). The objective of this study was 
to compare treatment effectiveness by HPV status based on a 
group of patients including those treated before and after CRT 
was adopted across the cancer centres of Ontario, Canada. 
Methods and Materials: A treatment-effectiveness and marker-
treatment interaction study of OPC patients treated for cure in 
1998, 1999, 2003 and 2004 from all treatment centres in Ontario 
who had available tissue for HPV testing. The patients were 
identified using the Ontario Cancer Registry and all charts were 
reviewed for demographic, patient, treatment and outcome 
factors. 865 patients were treated for cure and tissue was 
available on 610. Samples were tested for p16 and if negative 
were tested again using in-situ hybridization for HPV p16/18 viral 
DNA. We compared the survival of patients by HPV status and by 
treatment (RT versus CRT) using the Kaplan-Meier method and 
Cox Multiple Hazards regression models. 
Results: There were 392 HPV positive patients and 199 of the 610 
were treated with CRT. The HPV positive patients had 40% better 
overall survival (OS) and CRT improved OS by 15% over RT alone. 
However, there was no difference in OS comparing CRT to RT 
alone for the HPV positive patients (log rank p = 0.57) or for the 
HPV negative group (p = 0.15). When the multiple variable 
analysis was performed including HPV status and the interaction 
term with treatment, the HR for treatment (RT versus CRT) for 
HPV positive was 1.003 and for HPV negative was 1.036, and the 
p value for the interaction term was 0.91 indicating an outcome 
driven by HPV status not treatment type. 
Conclusions: In this study of real-world patients what appeared 
to be improvement in OS with the addition of concurrent 
chemotherapy to conventional radiotherapy was confounded by 
HPV status.  
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IMPACT OF TUMOUR VOLUME AND THE SURROGATE EFFECT OF 
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Purpose: With the advent of IMRT, distant metastasis (DM) has 
emerged as the most common cause of death in nasopharyngeal 
cancer (NPC). Lower neck lymph node (LWNK-LN) involvement is 
considered a poor prognostic factor and has traditionally been 
included in the most adverse N-category of the NPC TNM 
classification. NPC tends not to develop isolated spread to 
discontiguous lymph node (LN) echelons and LWNK-LN may 
correspondingly represent a continuum in the total burden of 
lymph node disease. This study evaluates whether tumour 
volume and the presence of LWNK-LN have independent 
influence on DM of NPC. 
Methods and Materials: All newly diagnosed NPC treated with 
IMRT +/- chemotherapy from 2005-2013 were reviewed. Primary 
(GTV-T) and nodal (GTV-N) volumes were delineated during IMRT 
treatment and subjected to institutional peer review. LWNK-LN 
was defined as level IV/Vb (any extension below the caudal 
border of the cricoid cartilage) based on the recently proposed 
8th edition TNM for NPC (Pan JJ, et al., Cancer 2016; 122(4):546-
58). Univariate (UVA) and multivariate (MVA) analyses was 
performed to evaluate prognostic significance of GTV-T, GTV-N 
and LWNK-LN for DM for the entire and LN-positive (N+) cohort. 
Results: A total of 344 NPC were identified including 52- N0, 87- 
N1, 158- N2, 16- N3a, and 31- N3b by 7th edition TNM. Median 
GTV-T was 25 cc (range: 1-253) and GTV-N was 14 cc (range: 0-
685). LWNK-LNs were present in 68 (19.7%) cases, all of which 
also had LNs in the upper neck. LWNK-LN were associated with 
higher GTV-N (p < 0.01). Median follow up was 5.6 years. In UVA, 
higher GTV-T (< 25 versus ≥ 25 cc) was associated with inferior 
five-year distant control (DC) [96% versus 78%; p < 0.001]. Higher 
GTV-N (< 14 versus ≥ 14 cc) was also associated with inferior five-
year DC [92% versus 82%; p = 0.02]. Presence of LWNK-LN was 
associated with inferior five-year DC [90% versus 75%; < 0.01]. 
MVA for DC showed that GTV-T [HR: 1.07 (1 -1.13), p < 0.01], 
GTV-N [HR: 1.1 (1.06-1.13), p = 0.03] and T classification [HR: 
2.71 (1.26 -5.83), p = 0.01] were prognostic while LWNK-LN was 
not [HR: 1.27 (0.65-2.47), p = 0.48]. Identical analyses confined 
to the N+ subset also confirmed the same findings that GTV-T 
[HR: 1.08 (1 -1.16), p = 0.04], GTV-N [HR: 1.09 (1.05-1.13), p < 
0.001] and T classification [HR: 2.36 (1.03 -5.40), p = 0.04] were 
prognostic for DC but LWNK-LN was not [HR: 1.31 (0.67-2.58), p 
= 0.43]. 
Conclusions: This study shows that primary and nodal volume are 
both prognostic for risk of DM after accounting for T and N 
classification. LWNK-LN has no apparent effect on DM risk after 
accounting for tumour volume, suggesting LWNK-LN is likely a 
surrogate of higher nodal volume rather than related to its 
anatomic location. 
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Purpose: Surgical transfer of the submandibular gland to the 
submental space in patients with non-oral head and neck cancer 
prior to adjuvant radiotherapy (RT) has previously been found to 
reduce the incidence of long-term xerostomia. Patients with oral 
cavity cancer are not candidates for the traditional 
submandibular gland transfer (SGT), as the submental space is 
commonly irradiated. A modified submandibular gland transfer 
(mSGT) technique was developed in which the contralateral 
gland is transferred to the peri-parotid space, lateral to the 
mandible. This study aimed to determine if the dose reduction 
to the submandibular gland achieved with mSGT results in mean 
doses below commonly accepted dose constraints, potentially 
reducing rates of longterm xerostomia. 
Methods and Materials: Sixteen consecutive patients with 
indications for adjuvant RT following surgery were enrolled. The 
mSGT was carried out at the time of oncologic resection. For 
each patient, a planning CT scan was performed and a RT plan 
was generated for volumetric-modulated arc therapy, with 
conformal avoidance of the transferred gland and parotid if the 
contralateral neck was pN0. The dose prescribed was 60 Gy in 30 
fractions to the tumour bed and involved nodal regions and 54 
Gy in 30 fractions to areas at risk of subclinical spread. Doses to 
the transferred gland and its original location in the 
submandibular triangle were compared. 
Results: In all patients the submandibular gland could be 
successfully transferred and adjuvant RT delivered according to 
protocol. The median dose to the transferred submandibular 
gland was 26.30 Gy (Range: 8.78 to 56.23 Gy) which was 
significantly lower than the median dose of 55.56 Gy to the 
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submandibular triangle (p < 0.0001). In 69% of patients (n = 11), 
the dose to the transferred submandibular gland was below the 
QUANTEC dose constraint of mean < 35 Gy. Four of the remaining 
patients had pathologic involvement of the contralateral level I 
nodes and could not have the transferred gland spared, while 
one patient had a large pT4 lip lesion and coverage of the tumour 
bed resulted in a dose of 36.0 Gy to the transferred gland. 
Conclusions: The mSGT technique significantly reduced the dose 
to the submandibular gland from a median dose very likely to 
produce xerostomia to a dose below accepted dose constraints. 
Adoption of this technique may reduce the rate of xerostomia 
and improve quality of life in patients with oral cavity cancer 
undergoing adjuvant RT. 
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THE BIOLOGICAL ROLE AND CLINICAL SIGNIFICANCE OF LONG 
NON-CODING RNA UROTHELIAL CARCINOMA ASSOCIATED 1 (UCA1) 
IN PROSTATE CANCER (PCA)  
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Purpose: Urothelial carcinoma-associated 1 (UCA1) is a recently 
identified long non-coding RNA which plays an oncologic role in 
several cancers and enhances cellular proliferation, invasion, 
and tumour growth. It is upregulated in prostate tumours, but its 
involvement in therapy response has not been investigated. 
Methods and Materials: To simulate the clinical scenario of 
ionizing-radiation resistance (IRR), we created IRR PCa cell lines 
by treatment with mock irradiation (parental cells) or IR 
(conventional fractionation (CF): 2 Gy daily X 59 for DU145-CF-
IRR cells). We performed gene array profiling to discover 
dysregulated genes in DU145-CF-IRR cells and identified UCA1. 
We investigated the mechanism of UCA1 on aggression and 
response to radiation and chemotherapy by performing miRNA 
comparative profiling (NanoString platform), Proteome Profiler 
Array, proliferation assays, soft agar colony formation, 
clonogenic assays, invasion assay, γ-H2AX assay, cell cycle 
profiling, MTS assay and western blotting. We also studied the 
clinical significance of UCA1 expression in two cohorts of PCa 
patients; CPC-GENE (n = 210; patients with intermediate-risk 
PCa) and MSKCC (n = 131; PCa patients treated with radical 
prostatectomy).  
Results: DU145-CF-IRR cells were radioresistant and acquired an 
aggressive phenotype. We found that UCA1 expression was 
significantly higher in DU145-CF-IRR compared to parental cells 
using gene array profiling and confirmatory qRT-PCR analysis 
(170-fold). Interestingly, UCA1 siRNA-knockdown reversed the 
aggressive phenotype and significantly increased sensitivity to IR 
and docetaxel. We demonstrated that UCA1 depletion inhibited 
growth, induced cell cycle arrest at the G2/M transition and 
decreased activation of the pro-survival Akt pathway. 
Furthermore, we found that UCA1 overexpression was associated 
with a trend toward lower biochemical recurrence-free survival 
in CPC-GENE patients (HR = 1.4, p = 0.28) and its aberrant 
expression was significantly associated with decreased five-year 
disease-free survival in publically available MSKCC database 
(84.5% versus 52%; HR = 2.19, log-rank test p = 0.005).  
Conclusions: We showed for the first time that UCA1 can 
influence cancer aggression, radiation and chemotherapy 
response in PCa, which may occur through altered Akt signaling. 
Our results also suggest that UCA1 can have prognostic value in 
PCa. Future work will investigate UCA1 as a therapeutic target 
and prognostic biomarker for PCa.  
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Purpose: Pain is experienced by 50%-75% of patients with bone 
metastases, representing a major source of morbidity amongst 
cancer patients. Magnetic Resonance- Guided High Intensity 
Focused Ultrasound (MRgHIFU) is a new, non-invasive, outpatient 
treatment modality for painful bone metastases. The aim of this 
study is to analyze urinary cytokines/chemokines pattern after 
MRgHIFU for palliative treatment of painful bone metastases. 
The findings will be compared to the cytokines/chemokines 
pattern post single 8 Gy fraction radiation from our previous 
study.  
Methods and Materials: Urine samples were collected from 
patients with painful bone metastases three days before and two 
days after treatment with MRgHIFU. Each urine sample was 
tested for pro-inflammatory cytokines and anti-inflammatory 
cytokines. Patients received teaching on how to collect urine 
samples on their own. The Millipore Milliplex 42-Plex Cyto-
kine/Chemokine Kit™ was used to measure urinary levels of a 
panel of cytokines/chemokines.  
Results: Ten patients were enrolled for the study and provided 
urine samples three days before and two days after treatment 
with MRgHIFU. The following fifteen cytokines were above the 
level of detection (LOD) in at least 50% of patients at both pre-
MRgHIFU and post-MRgHIFU: EGF, Eotaxin, Fit-3 Ligand, 
Fractalkine, G-CSF, GRO, IFN-alpha2, IL-1ra, IL-8, IP-10, MCP-1, 
PDGF-AA, RANTES, sIL-2Ra, and VEGF. Nine urinary cytokines 
significantly decreased post MRgHIFU, namely, Eotaxin, GRO, IL-
8, IL-13, IP-10, MCP-1, MIP-1beta, RANTES, and sIL_2Ra. In 
addition, there were significant differences between post 
MRgHIFU and post-8 Gy fraction radiation in most urinary 
cytokines. 
Conclusions: Nine urinary cytokines significantly decreased post 
MRgHIFU which correlated with pain response in patients with 
painful bone metastases. 
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UTILIZING METABOLIC ALTERATIONS INDUCED BY ADIPOSE 
DERIVED STROMAL CELLS TO IDENTIFY NOVEL DRUGS FOR THE 
TREATMENT OF RADIATION FIBROSIS  
Fei-Fei Liu  
Princess Margaret Cancer Centre, Toronto, ON 
Purpose: Radiation fibrosis (RF) is a side effect of radiotherapy 
characterized by irreversible scarring of normal tissue resulting 
in functional morbidity and decreased quality of life. Adipose-
derived stromal cells (ADSCs) have been shown to regulate the 
metabolic profile of target tissue through the secretion of 
cytokines and growth factors. We hypothesize that ADSCs may be 
therapeutically effective for RF through metabolic 
reprogramming and that these ADSC-mediated metabolic 
alterations can be utilized to identify novel drugs for the 
treatment of RF.  
Method: An RF model was created by radiating the hind limb of 
C3H mice. This model showed a dose dependent leg contracture 
and histological findings of fibrosis. Primary cultured ADSCs 
derived from C3H mice were identified based on 
immunophenotyping and their differentiation potential down the 
mesenchymal lineage. 
Results: ADSC transplantation was shown to be therapeutically 
effective for RF based on an improvement in leg contracture (p 
< 0.05) and reduced collagen deposition (p < 0.01). Whole 
transcriptome over-representation and gene set enrichment 
pathway analysis revealed that lipid metabolism and glycolysis 
were two pathways strongly dysregulated in RF and were 
reversed with ADSC treatment. To identify novel drugs to be 
repurposed for the treatment of RF, ADSC-mediated 
transcriptome alterations were compared with drug-mediated 
transcriptome alterations in CMAP, a pharmacogenomics 
